262
Views
12
CrossRef citations to date
0
Altmetric
Review

Muscular effects of statins in the elderly female: a review

, &
Pages 47-59 | Published online: 18 Jan 2013

References

  • National Center for Health StatisticsHealth, United States, 2010: With Special Feature on Death and DyingHyattsville (MD)National Center for Health Statistics2011
  • BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet20053661267127816214597
  • WalshJMEPignoneMDrug treatment for hyperlipidemia in womenJAMA20042912243225215138247
  • Heart Protection Study Collaborative GroupMRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
  • LemaitreRNFurbergCDNewmanABTime trends in the use of cholesterol-lowering agents in older adults: the cardiovascular health studyArch Intern Med1998158176117689738605
  • RallidisLSFountoulakiKAnastasiou-NanaMManaging the underestimated risk of statin-associated myopathyInt J Cardiol201215916917621813193
  • BaysHStatin safety: an overview and assessment of the data - 2005Am J Cardiol2006976C26C
  • IMS Institute for Health InformaticsThe Use of Medicines in the United States: Review of 2011Parsippany, NJIMS Institute for Health Informatics2012 Available from: http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdfAccessed October 15,2012
  • PasternakRCSmithSC JrBairey-MerzCNACC/AHA/NHLBI clinical advisory on the use and safety of statinsCirculation20021061024102812186811
  • McKenneyJMDavidsonMHJacobsonTAGuytonJRNational Lipid Association Statin Safety Assessment Task ForceFinal conclusions and recommendations of the national lipid association statin safety assessment task forceAm J Cardiol20069789C94C
  • SathasivamSStatin induced myotoxicityEur J Intern Med20122331732422560377
  • AlexanderKPBlazingMARosensonRSManagement of hyperlipidemia in older adultsJ Cardiovasc Pharmacol Ther200914495819124599
  • GaistDRodríguezLAHuertaCHallasJSindrupSHLipid-lowering drugs and risk of myopathy: a population-based follow-up studyEpidemiology20011256556911505177
  • JoyTRHegeleRANarrative review: statin-related myopathyAnn Intern Med200915085886819528564
  • LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med200573521425143515755765
  • ThompsonPDClarksonPKarasRHStatin-associated myopathyJAMA20032891681169012672737
  • NicholsGAKoroCEDoes statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patientsClin Ther2007291761177017919557
  • BruckertEHayemGDejagerSYauCBégaudBMild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO studyCardiovasc Drugs Ther20051940341416453090
  • NewmanCBSzarekMColhounHMThe safety and tolerability of atorvastatin 10 mg in the collaborative atorvastatin diabetes study (CARDS)Diab Vasc Dis Res2008517718318777490
  • BallantyneCMCorsiniADavidsonMHRisk for myopathy with statin therapy in high-risk patientsArch Intern Med200316355356412622602
  • EvansMReesAEffects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same?Drug Saf20022564966312137559
  • MillsEJWuPChongGEfficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trialsQJM201110410912420934984
  • InsullWJrIsaacsohnJKwiterovichPEfficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study GroupJ Int Med Res200828476810898118
  • JacobsonTAStatin safety: lessons from new drug applications for marketed statinsAm J Cardiol20069744C51C16377282
  • Center for Drug Evaluation and ResearchBaycol medical review1999 Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-740S008_Baycol_medr.pdfAccessed October 10, 2012
  • BoetjeMBunoutDBarreraGde la MazaMPLeivaLHirschSEffects of statin use on functional capacity and muscle mass in elderly womenAgeing Res201123539
  • KostisWJChengJQDobrzynskiJMCabreraJKostisJBMetaanalysis of statin effects in women versus menJ Am Coll Cardiol20125957258222300691
  • KunclRWAgents and mechanisms of toxic myopathyCurr Opin Neurol20092250651519680127
  • VaklavasCChatzizisisYSZiakasAZamboulisCGiannoglouGDMolecular basis of statin-associated myopathyAtherosclerosis2009202182818585718
  • NishimotoTTozawaRAmanoYWadaTImuraYSugiyamaYComparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytesBiochem Pharmacol2003662133213914609738
  • MatznoSYamauchiTGohdaMInhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblastsJ Lipid Res199738163916489300786
  • MarcoffLThompsonPDThe role of coenzyme Q10 in statin-associated myopathy: a systematic reviewJ Am Coll Cardiol2007492231223717560286
  • BeltowskiJWôjcickaGJamroz-WisniewskaAAdverse effects of statins - mechanisms and consequencesCurr Drug Saf2009420922819534648
  • ChatzizisisYSVaklavasCGiannoglouGDCoenzyme Q10 depletion: Etiopathogenic or predisposing factor in statin associated myopathy?Am J Cardiol2008101107118359340
  • BakerSKMolecular clues into the pathogenesis of statin-mediated muscle toxicityMuscle Nerve20053157258015712281
  • GuijarroCBlanco-ColioLMOrtegoM3-hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in cultureCirc Res1998834905009734471
  • GhatakAFaheemOThompsonPDThe genetics of statin-induced myopathyAtherosclerosis201021033734320042189
  • MangoniAAJacksonSHAge-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applicationsBr J Clin Pharmacol20045761414678335
  • ElDesokyESPharmacokinetic-pharmacodynamic crisis in the elderlyAm J Ther20071448849817890940
  • ParkerBAThompsonPDEffect of statins on skeletal muscle: exercise, myopathy, and muscle outcomesExerc Sport Sci Rev20124018819423000957
  • SzadkowskaIStanczykAAronowWSStatin therapy in the elderly: a reviewArch Gerontol Geriatr20105011411819217673
  • AndersonGDGender differences in pharmacological responseInt Rev Neurobiol20088311018929073
  • Hofer-DueckelmannCPrinzEBeindlWAdverse drug reactions (ADRs) associated with hospital admissions - elderly female patients are at highest riskInt J Clin Pharmacol Ther20114957758621961482
  • FattingerKRoosMVergèresPEpidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicineBr J Clin Pharmacol20004915816710671911
  • TranCKnowlesSRLiuBAShearNHGender differences in adverse drug reactionsJ Clin Pharmacol199838100310099824780
  • CicconeGKHoldcroftADrugs and sex differences: a review of drugs relating to anaesthesiaBr J Anaesth19998225526510365004
  • SicaDAGehrTWBRhabdomyolysis and statin therapy: relevance to the elderlyAm J Geriatr Cardiol200211485511773716
  • WolboldRKleinKBurkOSex is a major determinant of CYP3A4 expression in human liverHepatology20033897898814512885
  • GruerPJVegaJMMercuriMFDobrinskaMRTobertJAConcomitant use of cytochrome P450 3A4 inhibitors and simvastatinAm J Cardiol19998481181510513779
  • YoshidaMMatsumotoTSuzukiTKitamuraSMayamaTEffect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blockerPharmacoepidemiol Drug Saf200817707517918187
  • KaikkonenJNyyssönenKTuomainenTPRistonmaaUSalonenJTDeterminants of plasma coenzyme Q10 in humansFEB S Lett1999443163166
  • RacineMTousignant-LaflammeYKlodaLADionDDupuisGChoinièreMA systematic literature review of 10 years of research on sex/gender and pain perception - part 2: do biopsychosocial factors alter pain sensitivity differently in women and men? Pain201215361963522236999
  • GoffauxPMichaudKGaudreauJChalayePRainvillePMarchandSSex differences in perceived pain are affected by an anxious brainPain20111522065207321665365
  • VladutiuGDSimmonsZIsacksonPJGenetic risk factors associated with lipid-lowering drug-induced myopathiesMuscle Nerve20063415316216671104
  • LinkEParishSArmitageJSLC01B1 variants and statin-induced myopathy - a genome-wide studyN Engl J Med200835978979918650507
  • WilkeRARamseyLBJohnsonSGThe clinical pharmacogenomics implementation consortium: CPIC guideline for SLCOIBI and simvastatin-induced myopathyClin Pharmacol Ther20129211211722617227
  • PasanenMKFredriksonHNeuvonenPJNiemiMDifferent effects of SLCOIBI polymorphism on the pharmacokinetics of atorvastatin and rosuvastatinClin Pharmacol Ther20078272673317473846
  • BrunhamLRLansbergPJZhangLDifferential effect of the rs4149056 variant in SLCOIBI on myopathy associated with simvastatin and atorvastatinPharmacogenomics J20121223323721243006
  • SantosPCSoaresRANascimentoRMSLCOIBI rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic groupBMC Med Genet20111213621992719
  • RuanoGWindemuthAWuAHMechanisms of statin-induced myalgia assessed by physiogenomic associationsAtherosclerosis201121845145621868014
  • WilkeRAMooreJHBurmesterJKRelative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damagePharmacogenet Genomics20051541542115900215
  • ThompsonPDClarksonPMRosensonRSNational Lipid Association Statin Safety Task Force Muscle Safety Expert PanelAn assessment of statin safety by muscle expertsAm J Cardiol20069769C76C
  • BlomDJStatin therapy for the octogenarian? J Endocrinol Metab Diabetes South Afr2012173742
  • BresslerRBahlJJPrinciples of drug therapy for the elderly patientMayo Clin Proc2003781564157714661688
  • AroraRLieboMMaldonadoFStatin-induced myopathy: the two faces of JanusJ Cardiovasc Pharmacol Ther20061110511216891287
  • SchneckDWBirminghamBKZalikowskiJAThe effect of gemfibrozil on the pharmakonietics of rosuvastatinClin Pharmacol Ther20047545546315116058
  • CorsiniACeskaRDrug-drug interactions with statins: will pravastatin overcome the statins’ Achilles heel?Curr Med Res Opin2011271551156221682551
  • JonesPDavidsonMReporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statinAm J Cardiol20069512012215619408
  • NeuvonenPJNiemiMBackmanJTDrug interactions with lipid lowering drugs: mechanisms and clinical relevanceClin Pharmacol Ther20068056558117178259
  • ParkerBAAugeriALCapizziJAEffect of statins on creatine kinase levels before and after a marathon runAm J Cardiol201210928228722036108
  • HansenKEHildebrandJPFergusonEESteinJHOutcomes in 45 patients with statin-associated myopathyArch Intern Med20051652671267616344427
  • FrancSDejagerSBruckertEChauvenetMGiralPTurpinGA comprehensive description of muscle symptoms associated with lipid-lowering drugsCardiovasc Drugs Ther20031745946515107601
  • MascitelliLPezzettaFDoes statin therapy interfere with the ability of claudicant patients to exercise?Vasc Endovascular Surg20074147317942867
  • MarooBPLavieCJMilaniRVEfficacy and safety of intensive statin therapy in the elderlyAm J Geriatr Cardiol2008179210018326948
  • KulikARuelMStatins and coronary artery bypass graft surgery: preoperative and postoperatice efficacy and safetyExpert Opin Drug Saf2009855957119673591
  • DesaiHAronowWSAhnCIncidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statinsArch Gerontol Geriatr20105114915119819571
  • JickHZornbergGLJickSSSeshadriSDrachmanDAStatins and the risk of dementiaLancet20003561627163111089820
  • 78FreemanDJNorrieJSattarNPravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention StudyCirculation200110335736211136689
  • SpósitoACMansurAPCoelhoORNicolauJCRamiresJAAdditional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)Am J Cardiol1999831497149910335771
  • LeungBPSattarNCrillyAA novel anti-inflammatory role for simvastatin in inflammatory arthritisJ Immunol20031701524153012538717
  • LemoineSAlloucheSCoulbaultLMechanisms involved in cardioprotective effects of pravastatin administered during reoxygenation in human myocardium in vitroAnesthesiology201211682483322343498
  • OsmakMStatins and cancer: current and future prospectsCancer Lett201232411222542807
  • LutskiMShalevVPorathAChodickGContinuation with statin therapy and the risk of primary cancer: a population-based studyPrev Chronic Dis20129E131
  • SchneiderEBEfronDTMacKenzieEJRivaraFPNathensABJurkovichGJPremorbid statin use is associated with improved survival and functional outcomes in older head-injured individualsJ Trauma20117181581921986733
  • MarooBPLavieCJMilaniRVSecondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike? Drugs Aging20082564966418665658
  • KoDTMamdaniMAlterDALipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradoxJAMA20042911864187015100205
  • SirventPMercierJLacampagneANew insights into mechanisms of statin-associated myotoxicityCurr Opin Pharmacol2008833333818243052